SCHEMBL3545162

SCHEMBL3545162

Cc1cnn(-c2ccc([N+](=O)[O-])c(N3CCCCC3)c2)c1

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.61
ALDH1A1 P00352 9/20 0.61
CYP1A2 P05177 2/20 0.61
CYP2C19 P33261 2/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
NPSR1 Q6W5P4 5/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
MAPK1 P28482 3/20 0.55
HPGD P15428 2/20 0.52
POLB P06746 3/20 0.52
LMNA P02545 2/20 0.50
CSF1R P07333 1/20 0.48
CYP2C9 P11712 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5336011 0.94 MAPT (0.54) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1
SCHEMBL22094933 0.79 MAPT (0.97) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1
SCHEMBL3536564 0.79 MAPT (0.97) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1
SCHEMBL3539837 0.79 ALDH1A1 (0.59) MAPTALDH1A1L3MBTL1MAPK1POLB
SCHEMBL5095831 0.78 MAPT (0.64) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1
SCHEMBL25891601 0.78 ALDH1A1 (0.68) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1
SCHEMBL1225519 0.77 ALDH1A1 (0.45) MAPTALDH1A1HPGDLMNA
SCHEMBL3540453 0.76 CSF1R (0.53) MAPTALDH1A1SMN1; SMN2CSF1RMEN1
SCHEMBL8794400 0.76 ALDH1A1 (0.69) MAPTALDH1A1CYP1A2CYP2C19L3MBTL1
SCHEMBL23154022 0.75 HSP90AA1 (0.39) MAPTALDH1A1L3MBTL1NPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
CN-101084208-A Aromatic amides as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2007-12-05 CN disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES MAPT 159/4885ALDH1A1 4796/4885CYP1A2 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.